About / News

June 9, 2009

Alnylam and Cubist Report Preliminary Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus

more

June 5, 2009

Cubist Pharmaceuticals to Present at June 2009 Investor Conferences

more

May 19, 2009

Cubist Pharmaceuticals Ranks No. 1 in The Boston Globe's Annual Globe 100 List of Best Performing Companies

Cubist Lands Top Spot in First Appearance more

April 21, 2009

Cubist 1Q09 Total Net Revenues Up 37%

Total Net Revenues $121.1 Million Net Product Revenues $114.6 Million CUBICIN's 2009 Net U.S. Revenue Guidance Reconfirmed at $520-540 Million

GAAP Basic and Diluted Net Income of $0.14 and $0.13 Per Share, Respectively
NON-GAAP Basic and Diluted Net Income of $0.47 and $0.42 Per Share, Respectively

more

March 27, 2009

Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery

more

March 23, 2009

Cubist Pharmaceuticals Files Patent Infringement Lawsuit Against Teva Parenteral Medicines, Inc.

more

February 17, 2009

Phase 1 Trial Begins for Investigational New Drug for MDR Gram-negative Infections -- Second Phase 1 trial to emerge from Cubist's Labs in a week

more

February 13, 2009

Cubist Pharmaceuticals Announces Start of First-in-Human Clinical Trial for Investigational New Drug for Clostridium difficile infections

more

February 10, 2009

Cubist Plans to Commence Patent Infringement Litigation against Teva Parenteral Medicines, Inc. In Response To ANDA filing

Teva Parenteral Medicines, Inc. has submitted an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of CUBICIN(R) (daptomycin for injection). Cubist plans to file a patent infringement lawsuit against TPM in response to the ANDA filing. more

January 23, 2009

Cubist Pharmaceuticals Reports GAAP Diluted Net Income of $1.82 Per Share in Fourth Quarter 2008 and GAAP Diluted Net Income of $2.56 Per Share for Full Year 2008

Reversal of Cubist's Valuation Allowance for Deferred Tax Assets Benefits Tax Expense by Approximately $127.8 Million 2008 Non-GAAP Diluted Net Income of $1.86 Per Share Earnings Conference Call & Webcast Today (With Slides) at 5:00 p.m. ET more

January 12, 2009

Cubist Pharmaceuticals Announces Full Year 2008 Total Net Revenues of $433.6 Million

Full Year 2008 U.S. CUBICIN Net Product Revenues of $414.7 Million

Fourth Quarter 2008 U.S. CUBICIN Net Product Revenues of $120.1 Million more

October 16, 2008

Cubist Pharmaceuticals Q3 2008 Revenues Up 41%; Net Income Up 39%: Total Revenues $112.4 Million; CUBICIN® Net Product Revenues $110.6 Million

GAAP Basic and Diluted Net Income of $0.49 and $0.44 Per Share, Respectively NON-GAAP Basic and Diluted Net Income of $0.54 and $0.48 Per Share, Respectively

Earnings Conference Call & Webcast Today (With Slides) at 5:00 p.m. EDT more

September 30, 2008

Cubist Opens New Research Facility at Lexington Headquarters

more

July 2, 2008

Cubist to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.

- Leverages Proven U.S. Acute Care Sales Organization
- Complements Cubist's Gram-Positive CUBICIN more

June 24, 2008

Cubist Testifies on Need to Encourage Antibiotic Research and Development

Antimicrobial Resistance Reaching "Crisis Point" more

June 24, 2008

Cubist Appoints Mark H.N. Corrigan, M.D., to its Board of Directors

more